Organisation paid for research Program year 2025 Source: CMS Open Payments

Aventiv Research Phoenix

Neither a doctor nor a teaching hospital

Research payments

$96,148

93 payments

Through program year 2025, Aventiv Research Phoenix is reported as receiving $96,148 in research payments, across 93 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2025	Research	$3,973	81
2024	Research	$13,259	5
2023	Research	$15,598	3
2022	Research	$63,319	4

Breakdown

Who paid Research payments · program years 2022–2025

Boehringer Ingelheim International GmbH $55,523 88 payments
Boehringer Ingelheim Pharma GmbH & Co.KG $36,597 1 payment
Boehringer Ingelheim Pharmaceuticals, Inc. $4,029 4 payments

Studies the money was for Research payments · program years 2022–2025

Empa Kidney $73,382 3 payments
Obesity Long term safety in patients with CV risk $10,307 5 payments
Empa-Kidney $7,250 2 payments
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD $3,973 81 payments
Phase II dose finding PoCC in CKD $1,237 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.